» Articles » PMID: 23295441

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

Abstract

Background & Aims: Cholangiocarcinoma, the second most common liver cancer, can be classified as intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from a large series of patients.

Methods: We performed a gene expression profile, high-density single-nucleotide polymorphism array, and mutation analyses using formalin-fixed ICC samples from 149 patients. Associations with clinicopathologic traits and patient outcomes were examined for 119 cases. Class discovery was based on a non-negative matrix factorization algorithm and significant copy number variations were identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analysis. Gene set enrichment analysis was used to identify signaling pathways activated in specific molecular classes of tumors, and to analyze their genomic overlap with hepatocellular carcinoma (HCC).

Results: We identified 2 main biological classes of ICC. The inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation. The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC. Copy number variation-based clustering was able to refine these molecular groups further. We identified high-level amplifications in 5 regions, including 1p13 (9%) and 11q13.2 (4%), and several focal deletions, such as 9p21.3 (18%) and 14q22.1 (12% in coding regions for the SAV1 tumor suppressor). In a complementary approach, we identified a gene expression signature that was associated with reduced survival times of patients with ICC; this signature was enriched in the proliferation class (P < .001).

Conclusions: We used an integrative genomic analysis to identify 2 classes of ICC. The proliferation class has specific copy number alterations, activation of oncogenic pathways, and is associated with worse outcome. Different classes of ICC, based on molecular features, therefore might require different treatment approaches.

Citing Articles

Single-cell RNAseq reveals adverse metabolic transcriptional program in intrahepatic cholangiocarcinoma malignant cells.

Desterke C, Frances R, Monge C, Fu Y, Marchio A, Pineau P Biochem Biophys Rep. 2025; 41:101949.

PMID: 40034261 PMC: 11872667. DOI: 10.1016/j.bbrep.2025.101949.


CDK4/6 inhibitors upregulate cIAP1/2, and Smac mimetic LCL161 enhances their antitumor effects in cholangiocarcinoma cells.

Menapree P, Duangthim N, Sae-Fung A, Sonkaew S, Jitkaew S Sci Rep. 2025; 15(1):6826.

PMID: 40000765 PMC: 11861974. DOI: 10.1038/s41598-025-90997-y.


Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.

Villard C, Jorns C, Bergquist A eGastroenterology. 2025; 2(1):e100045.

PMID: 39944751 PMC: 11770459. DOI: 10.1136/egastro-2023-100045.


Unveiling the link between chronic inflammation and cancer.

Tripathi S, Sharma Y, Kumar D Metabol Open. 2025; 25:100347.

PMID: 39876904 PMC: 11772974. DOI: 10.1016/j.metop.2025.100347.


The Immune-Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies.

Cammarota A, Balsano R, Pressiani T, Bozzarelli S, Rimassa L, Lleo A Cancers (Basel). 2025; 17(2).

PMID: 39858054 PMC: 11763448. DOI: 10.3390/cancers17020272.


References
1.
Singh P, Patel T . Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol. 2006; 22(3):294-9. DOI: 10.1097/01.mog.0000218967.60633.64. View

2.
Lee K, Lee J, Kim T, Kim T, Park H, Byun J . The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; 107(18):8248-53. PMC: 2889558. DOI: 10.1073/pnas.0912203107. View

3.
Bromberg J, Wrzeszczynska M, Devgan G, Zhao Y, Pestell R, Albanese C . Stat3 as an oncogene. Cell. 1999; 98(3):295-303. DOI: 10.1016/s0092-8674(00)81959-5. View

4.
Hoshida Y, Nijman S, Kobayashi M, Chan J, Brunet J, Chiang D . Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69(18):7385-92. PMC: 3549578. DOI: 10.1158/0008-5472.CAN-09-1089. View

5.
Chin L, Andersen J, Futreal P . Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011; 17(3):297-303. DOI: 10.1038/nm.2323. View